MCRB Seres Therapeutics Inc

Price (delayed)

$6.95

Market cap

$67.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.18

Enterprise value

$109.3M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 10
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 22

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to ...

Highlights
MCRB's revenue is up by 45% since the previous quarter
Seres Therapeutics's gross profit has increased by 45% QoQ
Seres Therapeutics's net income has plunged by 164% YoY
The EPS has shrunk by 158% YoY

Key stats

What are the main financial stats of MCRB

MCRB stock price

How has the Seres Therapeutics stock price performed over time
Intraday
-3.07%
1 week
-8.31%
1 month
-9.62%
1 year
-2.52%
YTD
-53.29%
QTD
-21.65%

Financial performance

How have Seres Therapeutics's revenue and profit performed over time
Revenue
$1.15M
Gross profit
$1.15M
Operating income
-$87.64M
Net income
-$46.9M
Gross margin
100%
Net margin
-4,088.8%
Seres Therapeutics's net income has plunged by 164% YoY
MCRB's revenue is up by 45% since the previous quarter
Seres Therapeutics's gross profit has increased by 45% QoQ
The operating margin has grown by 36% from the previous quarter

Price vs fundamentals

How does MCRB's price correlate with its fundamentals

Growth

What is Seres Therapeutics's growth rate over time

Valuation

What is Seres Therapeutics stock price valuation
P/E
N/A
P/B
2.51
P/S
58.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
95.29
The EPS has shrunk by 158% YoY
The equity has decreased by 47% YoY and by 40% QoQ
The price to book (P/B) is 22% lower than the last 4 quarters average of 3.3
MCRB's revenue is up by 45% since the previous quarter

Efficiency

How efficient is Seres Therapeutics business performance
The company's return on assets has shrunk by 195% YoY
The return on invested capital has dropped by 186% year-on-year
Seres Therapeutics's ROE has plunged by 100% YoY

Dividends

What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MCRB.

Financial health

How did Seres Therapeutics financials performed over time
The total assets is 29% higher than the total liabilities
MCRB's current ratio is down by 36% QoQ and by 22% YoY
The quick ratio fell by 30% QoQ and by 11% YoY
Seres Therapeutics's debt to equity has surged by 72% YoY and by 62% QoQ
The equity has decreased by 47% YoY and by 40% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.